Sort by
Refine Your Search
-
, the central protein in the cascade. These include the first-ever therapy for geographic atrophy, a leading cause of blindness around the world, a therapy for paroxysmal nocturnal hemoglobinuria, a rare
-
targeting C3 therapies. There are two approved medicines targeting C3, the central protein in the cascade. These include the first-ever therapy for geographic atrophy, a leading cause of blindness around the
-
targeting C3 therapies. There are two approved medicines targeting C3, the central protein in the cascade. These include the first-ever therapy for geographic atrophy, a leading cause of blindness around the
Enter an email to receive alerts for protein-analysis "https:" positions